Skip to main content

Insight Molecular Diagnostics Inc.

corporate_fare Company Profile

Insight Molecular Diagnostics Inc.

IMDX·NASDAQ·Life Sciences·CIK 0001642380

Insight Molecular Diagnostics Inc. is a diagnostics technology company focused on expanding access to molecular diagnostic testing, particularly in transplanted organ rejection testing. The company develops molecular diagnostic test kits that allow customers to perform tests in-house, differing from the central laboratory model where samples are sent out for testing. This decentralized approach also supports researchers by enabling more studies. Insight Molecular Diagnostics Inc.'s initial target customers include hospitals, transplant centers, and laboratories. Key decision-makers for deploying their tests include doctors such as surgeons, nephrologists, and oncologists, as well as researchers, pathologists, lab directors, medical directors, department heads, lab managers, and chief medical officers. The company maintains a science-driven organization and generates intellectual property in its strategic target markets. Its intellectual property portfolio covers three main areas: organ transplant, oncology therapy selection, and oncology therapy monitoring. Within these categories, Insight Molecular Diagnostics Inc. has developed or is developing laboratory developed tests (LDTs) run at its Franklin, Tennessee laboratory, kitted research use only (RUO) tests, and in vitro diagnostic (IVD) kitted clinical tests for local labs. The primary near-term strategic market is organ transplant, where the company aims to provide a molecular diagnostic test kit for clinical use that decentralizes access to organ health testing for transplant patients. Enabling in-house testing is expected to create new value in the approximately $2 billion addressable market for kitted transplant rejection testing.

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for IMDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for IMDX spans 10-Q, 8-K, SCHEDULE 13D/A, 4.

Recent high-impact activity:

  • iMDx Prices $15M Offering at $1.75, a Discount to Its $1.66 Close
  • Cash-Strapped iMDx Launches Public Offering With Stock at 52-Week Low
  • iMDx Q2 Loss Deepens, Cash Runway Tightens; FDA Dialogue Continues
  • iMDx Q2 Loss Widens to $11.3M; FDA Seeks Additional Data on GraftAssureDx
  • FDA Advances GraftAssureDx Review, Requests Additional Info as iMDx Nears Authorization

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.05M
Net Income
-$50.22M
Diluted EPS
-$1.65
Op. Cash Flow
-$22.18M
Free Cash Flow
-$25.37M
Gross Profit
$2.3M
Operating Income
-$51.12M
Cash & Equivalents
$11.58M
Debt / Equity
0.00×
Net Margin
-12.39×
Shares Outstanding
28.68M sh
Source: 10-K · filed 2026-03-26 · accession 0001642380-26-000004

Short Interest & Short Volume

5.06 days to cover

FINRA reported short interest of 1,025,397 shares in IMDX as of the October 30, 2026 settlement, a 8.0% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 27.8% of IMDX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,025,397 shares as of October 30, 2026
Change vs prior period▲ 8.0%
Days to cover5.06 at avg daily volume of 202,771
Daily short volume (FINRA facilities)27.8% of 557,310 shares on November 20, 2026
5-day average short volume34.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for IMDX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-18.

1 recent capital raise

Offering Terms Finalized in Prospectus · Net Proceeds and Use

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with I →
$1.94 -1.52% today
52-week range · as of 2026-08-10 $1.94 – $8.51
Market cap
$64.53M
Volume
1.2M (4.4× avg)
3-mo avg 272.4K
Live data · 2026-11-21 16:09 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IMDX - Latest Insights

IMDX
Nov 17, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.66
Real-time Price: $1.94 info
Change: +$0.280 (+17%) info
Market Cap: $64.532M info
IMDX
Nov 16, 2026, 4:10 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.84
Real-time Price: $1.94 info
Change: +$0.100 (+5%) info
Market Cap: $64.532M info
IMDX
Aug 10, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.72
Real-time Price: $1.94 info
Change: -$2.78 (-59%) info
Market Cap: $64.532M info
IMDX
Aug 10, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.72
Real-time Price: $1.94 info
Change: -$2.78 (-59%) info
Market Cap: $64.532M info
IMDX
Aug 10, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.72
Real-time Price: $1.94 info
Change: -$2.78 (-59%) info
Market Cap: $64.532M info
IMDX
Jul 16, 2026, 3:22 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.63
Real-time Price: $1.94 info
Change: -$2.69 (-58%) info
Market Cap: $64.532M info
IMDX
Jun 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.32
Real-time Price: $1.94 info
Change: -$3.38 (-64%) info
Market Cap: $64.532M info
IMDX
Jun 16, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.32
Real-time Price: $1.94 info
Change: -$3.38 (-64%) info
Market Cap: $64.532M info
IMDX
May 13, 2026, 4:22 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.10
Real-time Price: $1.94 info
Change: -$3.16 (-62%) info
Market Cap: $64.532M info
IMDX
May 13, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.90
Real-time Price: $1.94 info
Change: -$2.96 (-60%) info
Market Cap: $64.532M info
IMDX
May 13, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.90
Real-time Price: $1.94 info
Change: -$2.96 (-60%) info
Market Cap: $64.532M info
IMDX
Apr 27, 2026, 7:14 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $3.96
Real-time Price: $1.94 info
Change: -$2.02 (-51%) info
Market Cap: $64.532M info
IMDX
Apr 27, 2026, 7:08 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $3.84
Real-time Price: $1.94 info
Change: -$1.90 (-49%) info
Market Cap: $64.532M info
IMDX
Apr 20, 2026, 7:24 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $3.99
Real-time Price: $1.94 info
Change: -$2.05 (-51%) info
Market Cap: $64.532M info
IMDX
Apr 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.92
Real-time Price: $1.94 info
Change: -$0.980 (-34%) info
Market Cap: $64.532M info
IMDX
Mar 26, 2026, 4:13 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $4.58
Real-time Price: $1.94 info
Change: -$2.64 (-58%) info
Market Cap: $64.532M info
IMDX
Mar 26, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.58
Real-time Price: $1.94 info
Change: -$2.64 (-58%) info
Market Cap: $64.532M info
IMDX
Mar 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.89
Real-time Price: $1.94 info
Change: -$2.95 (-60%) info
Market Cap: $64.532M info
IMDX
Mar 03, 2026, 8:07 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $4.94
Real-time Price: $1.94 info
Change: -$3.00 (-61%) info
Market Cap: $64.532M info
IMDX
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.10
Real-time Price: $1.94 info
Change: -$4.16 (-68%) info
Market Cap: $64.532M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets